data_1rws_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1rws _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.412 ' CB ' ' CB ' ' A' ' 20' ' ' ARG . . . . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 122.611 1.195 . . . . 0.0 109.928 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . . . -114.35 157.92 22.18 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 114.76 -1.109 . . . . 0.0 108.748 -178.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . . . -113.88 164.95 9.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 CA-C-O 122.295 1.045 . . . . 0.0 111.023 -174.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.865 ' O ' ' N ' ' A' ' 60' ' ' VAL . . . -137.56 142.17 41.36 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 105.82 -1.918 . . . . 0.0 105.82 178.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.427 ' HA ' ' O ' ' A' ' 60' ' ' VAL . . . -131.1 137.17 56.38 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.802 -173.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . 0.597 ' O ' ' HA ' ' A' ' 61' ' ' GLU . . . -142.84 155.56 44.8 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.245 -0.909 . . . . 0.0 109.299 177.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.85 ' O ' ' C ' ' A' ' 9' ' ' ILE . . . -89.16 129.7 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 120.487 -1.383 . . . . 0.0 110.241 -176.654 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.85 ' C ' ' O ' ' A' ' 8' ' ' VAL . . . -20.55 132.96 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.272 0 C-N-CA 115.714 -2.394 . . . . 0.0 107.283 -157.252 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.609 ' C ' ' O ' ' A' ' 9' ' ' ILE . . . 37.18 52.73 1.65 Allowed Glycine 0 N--CA 1.492 2.37 0 C-N-CA 117.486 -2.293 . . . . 0.0 109.767 175.009 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.638 ' O ' ' CB ' ' A' ' 12' ' ' ASN . . . -103.38 -13.48 16.64 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.701 -0.882 . . . . 0.0 110.525 178.321 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . 0.638 ' CB ' ' O ' ' A' ' 11' ' ' ARG . . . 88.55 53.4 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.263 0 O-C-N 120.771 -1.205 . . . . 0.0 111.743 176.179 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . . . -124.57 91.03 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 C-N-CA 117.085 -1.846 . . . . 0.0 113.043 -175.233 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . . . -93.55 135.59 34.67 Favored 'General case' 0 N--CA 1.498 1.926 0 CA-C-N 112.759 -2.018 . . . . 0.0 111.38 176.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LYS . . . . . 0.768 ' O ' ' O ' ' A' ' 16' ' ' GLU . . . -161.64 92.51 0.88 Allowed 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 176.149 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . 0.768 ' O ' ' O ' ' A' ' 15' ' ' LYS . . . -38.79 168.13 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.131 0 O-C-N 119.462 -2.024 . . . . 0.0 109.683 -169.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.612 ' O ' ' O ' ' A' ' 18' ' ' GLU . . . -160.33 115.8 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.563 0 C-N-CA 117.182 -1.807 . . . . 0.0 111.788 -168.422 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . 0.612 ' O ' ' O ' ' A' ' 17' ' ' ILE . . . -55.38 -137.33 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.199 0 CA-C-N 125.326 3.694 . . . . 0.0 109.592 -174.74 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . . . -179.87 -170.47 0.15 Allowed 'General case' 0 N--CA 1.496 1.871 0 N-CA-C 105.359 -2.089 . . . . 0.0 105.359 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . 0.412 ' CB ' ' CB ' ' A' ' 2' ' ' LYS . . . -161.07 -120.43 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.986 0 O-C-N 118.187 -2.821 . . . . 0.0 115.69 -166.498 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . . . -177.39 112.95 0.08 Allowed 'General case' 0 N--CA 1.502 2.127 0 O-C-N 118.484 -2.635 . . . . 0.0 109.958 -175.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 106.04 -27.05 18.75 Favored Glycine 0 N--CA 1.499 2.853 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 -177.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . . . -78.81 -170.63 2.23 Favored 'General case' 0 N--CA 1.512 2.638 0 N-CA-C 104.887 -2.264 . . . . 0.0 104.887 -178.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . . . -146.09 160.74 41.5 Favored 'General case' 0 C--N 1.266 -3.048 1 CA-C-N 107.544 -4.389 . . . . 0.0 110.479 -159.402 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.465 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -47.32 -61.71 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 O-C-N 119.252 -2.155 . . . . 0.0 110.658 161.627 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.465 ' C ' ' O ' ' A' ' 25' ' ' VAL . . . -40.56 -63.0 0.69 Allowed 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.326 -0.859 . . . . 0.0 109.074 -170.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.694 ' O ' ' N ' ' A' ' 30' ' ' ARG . . . -42.5 -66.28 0.38 Allowed 'General case' 0 N--CA 1.508 2.427 0 C-N-CA 117.999 -1.481 . . . . 0.0 111.406 177.436 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.566 ' C ' ' O ' ' A' ' 27' ' ' ASP . . . -41.95 -39.07 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 119.677 -1.889 . . . . 0.0 108.139 -174.038 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . . . -68.09 -35.73 78.64 Favored 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 115.161 -0.927 . . . . 0.0 108.802 176.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.694 ' N ' ' O ' ' A' ' 27' ' ' ASP . . . -56.29 -32.85 64.96 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.525 -0.734 . . . . 0.0 110.319 170.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -63.36 -14.52 51.0 Favored 'General case' 0 N--CA 1.51 2.545 0 C-N-CA 117.953 -1.499 . . . . 0.0 107.194 178.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.428 ' H ' ' C ' ' A' ' 30' ' ' ARG . . . -89.31 -11.89 10.1 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 172.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.593 ' N ' ' O ' ' A' ' 30' ' ' ARG . . . 75.07 28.89 61.48 Favored Glycine 0 N--CA 1.486 1.979 0 N-CA-C 104.694 -3.362 . . . . 0.0 104.694 -171.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.785 ' C ' ' H ' ' A' ' 36' ' ' THR . . . -150.75 101.52 2.93 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 -171.013 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . . . -61.07 46.89 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.966 0 O-C-N 119.796 -1.815 . . . . 0.0 108.444 161.396 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' THR . . . . . 0.785 ' H ' ' C ' ' A' ' 34' ' ' PHE . . . 51.62 89.6 0.03 OUTLIER 'General case' 0 N--CA 1.503 2.22 0 CA-C-O 117.425 -1.274 . . . . 0.0 109.129 -169.144 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . . . -100.55 -45.12 5.63 Favored 'General case' 0 N--CA 1.489 1.483 0 CA-C-N 124.815 3.462 . . . . 0.0 108.519 174.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.641 ' O ' ' CB ' ' A' ' 39' ' ' ALA . . . -79.38 64.91 4.4 Favored 'General case' 0 C--N 1.28 -2.445 0 CA-C-N 110.265 -3.152 . . . . 0.0 114.261 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.641 ' CB ' ' O ' ' A' ' 38' ' ' SER . . . 161.42 -173.03 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.255 0 C-N-CA 115.296 -2.561 . . . . 0.0 114.696 -179.039 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . . . -125.05 141.45 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 N-CA-C 105.134 -2.172 . . . . 0.0 105.134 165.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -109.42 146.44 34.47 Favored 'General case' 0 N--CA 1.494 1.749 0 CA-C-N 122.79 2.541 . . . . 0.0 111.101 -173.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LYS . . . . . 0.561 ' HA ' ' O ' ' A' ' 46' ' ' LYS . . . -145.78 107.72 4.33 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 118.523 -1.271 . . . . 0.0 110.308 -178.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . . . -97.19 138.64 21.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 118.833 -2.417 . . . . 0.0 111.888 -177.059 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . . . 51.8 27.39 4.16 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 120.03 -0.668 . . . . 0.0 109.807 -172.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 90.51 -2.4 80.53 Favored Glycine 0 N--CA 1.489 2.213 0 C-N-CA 115.98 -3.009 . . . . 0.0 110.689 173.213 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.561 ' O ' ' HA ' ' A' ' 42' ' ' LYS . . . -101.62 145.05 29.58 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . . . -87.39 159.65 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 CA-C-N 114.963 -1.017 . . . . 0.0 110.242 -174.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . . . -155.22 -176.66 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.767 0 C-N-CA 115.38 -2.528 . . . . 0.0 111.892 -178.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . . . -111.83 -176.35 2.91 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 119.562 -1.961 . . . . 0.0 108.049 168.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . . . -63.45 -31.97 73.28 Favored 'General case' 0 N--CA 1.512 2.625 0 C-N-CA 126.733 2.013 . . . . 0.0 108.998 178.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . . . -100.99 -10.54 20.46 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.316 -0.865 . . . . 0.0 110.827 -177.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.543 ' O ' ' C ' ' A' ' 53' ' ' GLU . . . -78.9 97.66 6.09 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.222 -1.391 . . . . 0.0 108.139 -176.088 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.543 ' C ' ' O ' ' A' ' 52' ' ' ASP . . . -35.19 167.25 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.44 0 O-C-N 119.964 -1.71 . . . . 0.0 113.213 -163.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.475 ' CB ' ' CB ' ' A' ' 58' ' ' ASP . . . -101.4 -167.66 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 N-CA-C 101.944 -3.354 . . . . 0.0 101.944 156.471 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LYS . . . . . 0.698 ' O ' ' CB ' ' A' ' 56' ' ' ASP . . . -162.81 144.36 10.13 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 173.808 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ASP . . . . . 0.698 ' CB ' ' O ' ' A' ' 55' ' ' LYS . . . 88.41 7.48 0.16 Allowed 'General case' 0 C--N 1.292 -1.909 0 N-CA-C 117.267 2.321 . . . . 0.0 117.267 161.091 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.05 57.63 1.89 Allowed Glycine 0 N--CA 1.486 2.029 0 N-CA-C 106.939 -2.464 . . . . 0.0 106.939 -166.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.475 ' CB ' ' CB ' ' A' ' 54' ' ' VAL . . . -71.5 155.58 40.42 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 106.556 -1.646 . . . . 0.0 106.556 173.096 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 0.595 ' C ' ' O ' ' A' ' 5' ' ' LYS . . . -81.5 -134.99 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.937 1 N-CA-C 99.535 -4.246 . . . . 0.0 99.535 -169.373 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.865 ' N ' ' O ' ' A' ' 5' ' ' LYS . . . -151.21 133.62 6.14 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 CA-C-N 110.513 -3.04 . . . . 0.0 107.583 157.317 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . 0.597 ' HA ' ' O ' ' A' ' 7' ' ' LYS . . . -112.19 125.63 54.34 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 117.779 -3.076 . . . . 0.0 108.886 171.233 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.631 ' O ' ' CB ' ' A' ' 63' ' ' ILE . . . -144.21 114.16 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 C-N-CA 118.566 -1.254 . . . . 0.0 111.934 177.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ILE . . . . . 0.704 ' O ' ' N ' ' A' ' 65' ' ' VAL . . . 154.66 149.98 0.0 OUTLIER Pre-proline 0 C--N 1.301 -1.505 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -178.58 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' PRO . . . . . 0.535 ' O ' ' N ' ' A' ' 66' ' ' VAL . . . -31.91 70.26 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.608 0 C-N-CA 124.005 3.136 . . . . 0.0 113.787 -174.627 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . 0.704 ' N ' ' O ' ' A' ' 63' ' ' ILE . . . -58.39 62.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.256 -0.903 . . . . 0.0 111.904 -177.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.535 ' N ' ' O ' ' A' ' 64' ' ' PRO . . . -101.77 83.49 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 119.447 -2.033 . . . . 0.0 109.257 -179.784 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . . . -72.31 112.24 8.22 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.975 -1.078 . . . . 0.0 108.364 -178.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . -176.17 -5.82 0.02 OUTLIER Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.98 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.412 ' CB ' ' CB ' ' A' ' 20' ' ' ARG . . . . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 122.611 1.195 . . . . 0.0 109.928 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . . . -114.35 157.92 22.18 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 114.76 -1.109 . . . . 0.0 108.748 -178.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . . . -113.88 164.95 9.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 CA-C-O 122.295 1.045 . . . . 0.0 111.023 -174.541 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.865 ' O ' ' N ' ' A' ' 60' ' ' VAL . . . -137.56 142.17 41.36 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 105.82 -1.918 . . . . 0.0 105.82 178.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.455 ' HA ' ' O ' ' A' ' 60' ' ' VAL . . . -131.1 137.17 56.38 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.802 -173.472 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.586 ' O ' ' HA ' ' A' ' 61' ' ' GLU . . . -142.84 155.56 44.8 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.245 -0.909 . . . . 0.0 109.299 177.826 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.85 ' O ' ' C ' ' A' ' 9' ' ' ILE . . . -89.16 129.7 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 120.487 -1.383 . . . . 0.0 110.241 -176.654 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.85 ' C ' ' O ' ' A' ' 8' ' ' VAL . . . -20.55 132.96 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.272 0 C-N-CA 115.714 -2.394 . . . . 0.0 107.283 -157.252 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.609 ' C ' ' O ' ' A' ' 9' ' ' ILE . . . 37.18 52.73 1.65 Allowed Glycine 0 N--CA 1.492 2.37 0 C-N-CA 117.486 -2.293 . . . . 0.0 109.767 175.009 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.638 ' O ' ' CB ' ' A' ' 12' ' ' ASN . . . -103.38 -13.48 16.64 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.701 -0.882 . . . . 0.0 110.525 178.321 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASN . . . . . 0.638 ' CB ' ' O ' ' A' ' 11' ' ' ARG . . . 88.55 53.4 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.263 0 O-C-N 120.771 -1.205 . . . . 0.0 111.743 176.179 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . . . -124.57 91.03 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 C-N-CA 117.085 -1.846 . . . . 0.0 113.043 -175.233 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . . . -93.55 135.59 34.67 Favored 'General case' 0 N--CA 1.498 1.926 0 CA-C-N 112.759 -2.018 . . . . 0.0 111.38 176.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LYS . . . . . 0.768 ' O ' ' O ' ' A' ' 16' ' ' GLU . . . -161.64 92.51 0.88 Allowed 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 176.149 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLU . . . . . 0.768 ' O ' ' O ' ' A' ' 15' ' ' LYS . . . -38.79 168.13 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.131 0 O-C-N 119.462 -2.024 . . . . 0.0 109.683 -169.884 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.612 ' O ' ' O ' ' A' ' 18' ' ' GLU . . . -160.33 115.8 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.563 0 C-N-CA 117.182 -1.807 . . . . 0.0 111.788 -168.422 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLU . . . . . 0.612 ' O ' ' O ' ' A' ' 17' ' ' ILE . . . -55.38 -137.33 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.199 0 CA-C-N 125.326 3.694 . . . . 0.0 109.592 -174.74 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.409 ' N ' ' HA ' ' A' ' 2' ' ' LYS . . . -179.87 -170.47 0.15 Allowed 'General case' 0 N--CA 1.496 1.871 0 N-CA-C 105.359 -2.089 . . . . 0.0 105.359 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.412 ' CB ' ' CB ' ' A' ' 2' ' ' LYS . . . -161.07 -120.43 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.986 0 O-C-N 118.187 -2.821 . . . . 0.0 115.69 -166.498 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . . . -177.39 112.95 0.08 Allowed 'General case' 0 N--CA 1.502 2.127 0 O-C-N 118.484 -2.635 . . . . 0.0 109.958 -175.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 106.04 -27.05 18.75 Favored Glycine 0 N--CA 1.499 2.853 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 -177.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . . . -78.81 -170.63 2.23 Favored 'General case' 0 N--CA 1.512 2.638 0 N-CA-C 104.887 -2.264 . . . . 0.0 104.887 -178.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . . . -146.09 160.74 41.5 Favored 'General case' 0 C--N 1.266 -3.048 1 CA-C-N 107.544 -4.389 . . . . 0.0 110.479 -159.402 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.505 ' CB ' ' HA ' ' A' ' 53' ' ' GLU . . . -47.32 -61.71 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 O-C-N 119.252 -2.155 . . . . 0.0 110.658 161.627 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.465 ' C ' ' O ' ' A' ' 25' ' ' VAL . . . -40.56 -63.0 0.69 Allowed 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.326 -0.859 . . . . 0.0 109.074 -170.528 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.694 ' O ' ' N ' ' A' ' 30' ' ' ARG . . . -42.5 -66.28 0.38 Allowed 'General case' 0 N--CA 1.508 2.427 0 C-N-CA 117.999 -1.481 . . . . 0.0 111.406 177.436 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.566 ' C ' ' O ' ' A' ' 27' ' ' ASP . . . -41.95 -39.07 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 119.677 -1.889 . . . . 0.0 108.139 -174.038 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . . . -68.09 -35.73 78.64 Favored 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 115.161 -0.927 . . . . 0.0 108.802 176.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.694 ' N ' ' O ' ' A' ' 27' ' ' ASP . . . -56.29 -32.85 64.96 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.525 -0.734 . . . . 0.0 110.319 170.849 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -63.36 -14.52 51.0 Favored 'General case' 0 N--CA 1.51 2.545 0 C-N-CA 117.953 -1.499 . . . . 0.0 107.194 178.682 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . . . -89.31 -11.89 10.1 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 172.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.526 ' N ' ' O ' ' A' ' 30' ' ' ARG . . . 75.07 28.89 61.48 Favored Glycine 0 N--CA 1.486 1.979 0 N-CA-C 104.694 -3.362 . . . . 0.0 104.694 -171.896 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.774 ' O ' ' N ' ' A' ' 36' ' ' THR . . . -150.75 101.52 2.93 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 -171.013 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . . . -61.07 46.89 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.966 0 O-C-N 119.796 -1.815 . . . . 0.0 108.444 161.396 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' THR . . . . . 0.774 ' N ' ' O ' ' A' ' 34' ' ' PHE . . . 51.62 89.6 0.03 OUTLIER 'General case' 0 N--CA 1.503 2.22 0 CA-C-O 117.425 -1.274 . . . . 0.0 109.129 -169.144 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . . . -100.55 -45.12 5.63 Favored 'General case' 0 N--CA 1.489 1.483 0 CA-C-N 124.815 3.462 . . . . 0.0 108.519 174.243 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.881 ' O ' ' HB2' ' A' ' 39' ' ' ALA . . . -79.38 64.91 4.4 Favored 'General case' 0 C--N 1.28 -2.445 0 CA-C-N 110.265 -3.152 . . . . 0.0 114.261 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.881 ' HB2' ' O ' ' A' ' 38' ' ' SER . . . 161.42 -173.03 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.255 0 C-N-CA 115.296 -2.561 . . . . 0.0 114.696 -179.039 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . . . -125.05 141.45 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 N-CA-C 105.134 -2.172 . . . . 0.0 105.134 165.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -109.42 146.44 34.47 Favored 'General case' 0 N--CA 1.494 1.749 0 CA-C-N 122.79 2.541 . . . . 0.0 111.101 -173.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LYS . . . . . 0.612 ' HA ' ' O ' ' A' ' 46' ' ' LYS . . . -145.78 107.72 4.33 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 118.523 -1.271 . . . . 0.0 110.308 -178.539 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . . . -97.19 138.64 21.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 118.833 -2.417 . . . . 0.0 111.888 -177.059 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . . . 51.8 27.39 4.16 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 120.03 -0.668 . . . . 0.0 109.807 -172.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 90.51 -2.4 80.53 Favored Glycine 0 N--CA 1.489 2.213 0 C-N-CA 115.98 -3.009 . . . . 0.0 110.689 173.213 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.612 ' O ' ' HA ' ' A' ' 42' ' ' LYS . . . -101.62 145.05 29.58 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . . . -87.39 159.65 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 CA-C-N 114.963 -1.017 . . . . 0.0 110.242 -174.65 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . . . -155.22 -176.66 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.767 0 C-N-CA 115.38 -2.528 . . . . 0.0 111.892 -178.243 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . . . -111.83 -176.35 2.91 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 119.562 -1.961 . . . . 0.0 108.049 168.523 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . . . -63.45 -31.97 73.28 Favored 'General case' 0 N--CA 1.512 2.625 0 C-N-CA 126.733 2.013 . . . . 0.0 108.998 178.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . . . -100.99 -10.54 20.46 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.316 -0.865 . . . . 0.0 110.827 -177.513 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.543 ' O ' ' C ' ' A' ' 53' ' ' GLU . . . -78.9 97.66 6.09 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.222 -1.391 . . . . 0.0 108.139 -176.088 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.543 ' C ' ' O ' ' A' ' 52' ' ' ASP . . . -35.19 167.25 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.44 0 O-C-N 119.964 -1.71 . . . . 0.0 113.213 -163.168 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.475 ' CB ' ' CB ' ' A' ' 58' ' ' ASP . . . -101.4 -167.66 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 N-CA-C 101.944 -3.354 . . . . 0.0 101.944 156.471 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LYS . . . . . 0.698 ' O ' ' CB ' ' A' ' 56' ' ' ASP . . . -162.81 144.36 10.13 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 173.808 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ASP . . . . . 0.698 ' CB ' ' O ' ' A' ' 55' ' ' LYS . . . 88.41 7.48 0.16 Allowed 'General case' 0 C--N 1.292 -1.909 0 N-CA-C 117.267 2.321 . . . . 0.0 117.267 161.091 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.05 57.63 1.89 Allowed Glycine 0 N--CA 1.486 2.029 0 N-CA-C 106.939 -2.464 . . . . 0.0 106.939 -166.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.475 ' CB ' ' CB ' ' A' ' 54' ' ' VAL . . . -71.5 155.58 40.42 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 106.556 -1.646 . . . . 0.0 106.556 173.096 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.595 ' C ' ' O ' ' A' ' 5' ' ' LYS . . . -81.5 -134.99 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.937 1 N-CA-C 99.535 -4.246 . . . . 0.0 99.535 -169.373 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.865 ' N ' ' O ' ' A' ' 5' ' ' LYS . . . -151.21 133.62 6.14 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 CA-C-N 110.513 -3.04 . . . . 0.0 107.583 157.317 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLU . . . . . 0.586 ' HA ' ' O ' ' A' ' 7' ' ' LYS . . . -112.19 125.63 54.34 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 117.779 -3.076 . . . . 0.0 108.886 171.233 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.743 ' HA ' ' HB2' ' A' ' 39' ' ' ALA . . . -144.21 114.16 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 C-N-CA 118.566 -1.254 . . . . 0.0 111.934 177.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ILE . . . . . 0.704 ' O ' ' N ' ' A' ' 65' ' ' VAL . . . 154.66 149.98 0.0 OUTLIER Pre-proline 0 C--N 1.301 -1.505 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -178.58 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 66' ' ' VAL . . . -31.91 70.26 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.608 0 C-N-CA 124.005 3.136 . . . . 0.0 113.787 -174.627 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.704 ' N ' ' O ' ' A' ' 63' ' ' ILE . . . -58.39 62.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.256 -0.903 . . . . 0.0 111.904 -177.67 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.545 ' N ' ' O ' ' A' ' 64' ' ' PRO . . . -101.77 83.49 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 119.447 -2.033 . . . . 0.0 109.257 -179.784 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . . . -72.31 112.24 8.22 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.975 -1.078 . . . . 0.0 108.364 -178.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLY . . . . . 0.412 ' H ' ' H ' ' A' ' 69' ' ' GLY . . . -176.17 -5.82 0.02 OUTLIER Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLY . . . . . 0.412 ' H ' ' H ' ' A' ' 68' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.412 ' CB ' ' CB ' ' A' ' 20' ' ' ARG . . . . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 122.611 1.195 . . . . 0.0 109.928 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' MET . . . . . . . . . . . . . . . -114.35 157.92 22.18 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 114.76 -1.109 . . . . 0.0 108.748 -178.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . . . -113.88 164.95 9.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.622 0 CA-C-O 122.295 1.045 . . . . 0.0 111.023 -174.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.865 ' O ' ' N ' ' A' ' 60' ' ' VAL . . . -137.56 142.17 41.36 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 105.82 -1.918 . . . . 0.0 105.82 178.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.455 ' HA ' ' O ' ' A' ' 60' ' ' VAL . . . -131.1 137.17 56.38 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.802 -173.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.586 ' O ' ' HA ' ' A' ' 61' ' ' GLU . . . -142.84 155.56 44.8 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.245 -0.909 . . . . 0.0 109.299 177.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.85 ' O ' ' C ' ' A' ' 9' ' ' ILE . . . -89.16 129.7 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 120.487 -1.383 . . . . 0.0 110.241 -176.654 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.85 ' C ' ' O ' ' A' ' 8' ' ' VAL . . . -20.55 132.96 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.272 0 C-N-CA 115.714 -2.394 . . . . 0.0 107.283 -157.252 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.609 ' C ' ' O ' ' A' ' 9' ' ' ILE . . . 37.18 52.73 1.65 Allowed Glycine 0 N--CA 1.492 2.37 0 C-N-CA 117.486 -2.293 . . . . 0.0 109.767 175.009 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.638 ' O ' ' CB ' ' A' ' 12' ' ' ASN . . . -103.38 -13.48 16.64 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.701 -0.882 . . . . 0.0 110.525 178.321 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . 0.638 ' CB ' ' O ' ' A' ' 11' ' ' ARG . . . 88.55 53.4 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.263 0 O-C-N 120.771 -1.205 . . . . 0.0 111.743 176.179 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . . . -124.57 91.03 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 C-N-CA 117.085 -1.846 . . . . 0.0 113.043 -175.233 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . . . -93.55 135.59 34.67 Favored 'General case' 0 N--CA 1.498 1.926 0 CA-C-N 112.759 -2.018 . . . . 0.0 111.38 176.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LYS . . . . . 0.768 ' O ' ' O ' ' A' ' 16' ' ' GLU . . . -161.64 92.51 0.88 Allowed 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 176.149 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . 0.768 ' O ' ' O ' ' A' ' 15' ' ' LYS . . . -38.79 168.13 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.131 0 O-C-N 119.462 -2.024 . . . . 0.0 109.683 -169.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.612 ' O ' ' O ' ' A' ' 18' ' ' GLU . . . -160.33 115.8 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.51 2.563 0 C-N-CA 117.182 -1.807 . . . . 0.0 111.788 -168.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . 0.612 ' O ' ' O ' ' A' ' 17' ' ' ILE . . . -55.38 -137.33 0.0 OUTLIER 'General case' 0 N--CA 1.503 2.199 0 CA-C-N 125.326 3.694 . . . . 0.0 109.592 -174.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.409 ' N ' ' HA ' ' A' ' 2' ' ' LYS . . . -179.87 -170.47 0.15 Allowed 'General case' 0 N--CA 1.496 1.871 0 N-CA-C 105.359 -2.089 . . . . 0.0 105.359 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.412 ' CB ' ' CB ' ' A' ' 2' ' ' LYS . . . -161.07 -120.43 0.02 OUTLIER 'General case' 0 N--CA 1.499 1.986 0 O-C-N 118.187 -2.821 . . . . 0.0 115.69 -166.498 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . . . -177.39 112.95 0.08 Allowed 'General case' 0 N--CA 1.502 2.127 0 O-C-N 118.484 -2.635 . . . . 0.0 109.958 -175.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 106.04 -27.05 18.75 Favored Glycine 0 N--CA 1.499 2.853 0 N-CA-C 110.012 -1.235 . . . . 0.0 110.012 -177.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . . . -78.81 -170.63 2.23 Favored 'General case' 0 N--CA 1.512 2.638 0 N-CA-C 104.887 -2.264 . . . . 0.0 104.887 -178.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LYS . . . . . . . . . . . . . . . -146.09 160.74 41.5 Favored 'General case' 0 C--N 1.266 -3.048 1 CA-C-N 107.544 -4.389 . . . . 0.0 110.479 -159.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.505 ' CB ' ' HA ' ' A' ' 53' ' ' GLU . . . -47.32 -61.71 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.069 0 O-C-N 119.252 -2.155 . . . . 0.0 110.658 161.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.465 ' C ' ' O ' ' A' ' 25' ' ' VAL . . . -40.56 -63.0 0.69 Allowed 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.326 -0.859 . . . . 0.0 109.074 -170.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.694 ' O ' ' N ' ' A' ' 30' ' ' ARG . . . -42.5 -66.28 0.38 Allowed 'General case' 0 N--CA 1.508 2.427 0 C-N-CA 117.999 -1.481 . . . . 0.0 111.406 177.436 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.566 ' C ' ' O ' ' A' ' 27' ' ' ASP . . . -41.95 -39.07 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 119.677 -1.889 . . . . 0.0 108.139 -174.038 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . . . -68.09 -35.73 78.64 Favored 'General case' 0 C--N 1.29 -2.013 0 CA-C-N 115.161 -0.927 . . . . 0.0 108.802 176.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.694 ' N ' ' O ' ' A' ' 27' ' ' ASP . . . -56.29 -32.85 64.96 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.525 -0.734 . . . . 0.0 110.319 170.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -63.36 -14.52 51.0 Favored 'General case' 0 N--CA 1.51 2.545 0 C-N-CA 117.953 -1.499 . . . . 0.0 107.194 178.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . . . -89.31 -11.89 10.1 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 N-CA-C 107.279 -1.378 . . . . 0.0 107.279 172.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.526 ' N ' ' O ' ' A' ' 30' ' ' ARG . . . 75.07 28.89 61.48 Favored Glycine 0 N--CA 1.486 1.979 0 N-CA-C 104.694 -3.362 . . . . 0.0 104.694 -171.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.774 ' O ' ' N ' ' A' ' 36' ' ' THR . . . -150.75 101.52 2.93 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 -171.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . . . -61.07 46.89 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.966 0 O-C-N 119.796 -1.815 . . . . 0.0 108.444 161.396 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' THR . . . . . 0.774 ' N ' ' O ' ' A' ' 34' ' ' PHE . . . 51.62 89.6 0.03 OUTLIER 'General case' 0 N--CA 1.503 2.22 0 CA-C-O 117.425 -1.274 . . . . 0.0 109.129 -169.144 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . . . -100.55 -45.12 5.63 Favored 'General case' 0 N--CA 1.489 1.483 0 CA-C-N 124.815 3.462 . . . . 0.0 108.519 174.243 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.881 ' O ' ' HB2' ' A' ' 39' ' ' ALA . . . -79.38 64.91 4.4 Favored 'General case' 0 C--N 1.28 -2.445 0 CA-C-N 110.265 -3.152 . . . . 0.0 114.261 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.881 ' HB2' ' O ' ' A' ' 38' ' ' SER . . . 161.42 -173.03 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.255 0 C-N-CA 115.296 -2.561 . . . . 0.0 114.696 -179.039 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . . . . . . . . . . . -125.05 141.45 45.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 N-CA-C 105.134 -2.172 . . . . 0.0 105.134 165.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ALA . . . . . . . . . . . . . . . -109.42 146.44 34.47 Favored 'General case' 0 N--CA 1.494 1.749 0 CA-C-N 122.79 2.541 . . . . 0.0 111.101 -173.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LYS . . . . . 0.612 ' HA ' ' O ' ' A' ' 46' ' ' LYS . . . -145.78 107.72 4.33 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 118.523 -1.271 . . . . 0.0 110.308 -178.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . . . -97.19 138.64 21.59 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 118.833 -2.417 . . . . 0.0 111.888 -177.059 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . . . 51.8 27.39 4.16 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 120.03 -0.668 . . . . 0.0 109.807 -172.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 90.51 -2.4 80.53 Favored Glycine 0 N--CA 1.489 2.213 0 C-N-CA 115.98 -3.009 . . . . 0.0 110.689 173.213 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.612 ' O ' ' HA ' ' A' ' 42' ' ' LYS . . . -101.62 145.05 29.58 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . . . -87.39 159.65 3.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 CA-C-N 114.963 -1.017 . . . . 0.0 110.242 -174.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . . . -155.22 -176.66 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.767 0 C-N-CA 115.38 -2.528 . . . . 0.0 111.892 -178.243 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . . . -111.83 -176.35 2.91 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 119.562 -1.961 . . . . 0.0 108.049 168.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . . . -63.45 -31.97 73.28 Favored 'General case' 0 N--CA 1.512 2.625 0 C-N-CA 126.733 2.013 . . . . 0.0 108.998 178.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . . . -100.99 -10.54 20.46 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.316 -0.865 . . . . 0.0 110.827 -177.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.543 ' O ' ' C ' ' A' ' 53' ' ' GLU . . . -78.9 97.66 6.09 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.222 -1.391 . . . . 0.0 108.139 -176.088 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.543 ' C ' ' O ' ' A' ' 52' ' ' ASP . . . -35.19 167.25 0.0 OUTLIER 'General case' 0 C--N 1.303 -1.44 0 O-C-N 119.964 -1.71 . . . . 0.0 113.213 -163.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.475 ' CB ' ' CB ' ' A' ' 58' ' ' ASP . . . -101.4 -167.66 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 N-CA-C 101.944 -3.354 . . . . 0.0 101.944 156.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LYS . . . . . 0.698 ' O ' ' CB ' ' A' ' 56' ' ' ASP . . . -162.81 144.36 10.13 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 173.808 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ASP . . . . . 0.698 ' CB ' ' O ' ' A' ' 55' ' ' LYS . . . 88.41 7.48 0.16 Allowed 'General case' 0 C--N 1.292 -1.909 0 N-CA-C 117.267 2.321 . . . . 0.0 117.267 161.091 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 88.05 57.63 1.89 Allowed Glycine 0 N--CA 1.486 2.029 0 N-CA-C 106.939 -2.464 . . . . 0.0 106.939 -166.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.475 ' CB ' ' CB ' ' A' ' 54' ' ' VAL . . . -71.5 155.58 40.42 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 106.556 -1.646 . . . . 0.0 106.556 173.096 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.595 ' C ' ' O ' ' A' ' 5' ' ' LYS . . . -81.5 -134.99 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.937 1 N-CA-C 99.535 -4.246 . . . . 0.0 99.535 -169.373 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.865 ' N ' ' O ' ' A' ' 5' ' ' LYS . . . -151.21 133.62 6.14 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 CA-C-N 110.513 -3.04 . . . . 0.0 107.583 157.317 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . 0.586 ' HA ' ' O ' ' A' ' 7' ' ' LYS . . . -112.19 125.63 54.34 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 117.779 -3.076 . . . . 0.0 108.886 171.233 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.743 ' HA ' ' HB2' ' A' ' 39' ' ' ALA . . . -144.21 114.16 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 C-N-CA 118.566 -1.254 . . . . 0.0 111.934 177.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ILE . . . . . 0.704 ' O ' ' N ' ' A' ' 65' ' ' VAL . . . 154.66 149.98 0.0 OUTLIER Pre-proline 0 C--N 1.301 -1.505 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -178.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 66' ' ' VAL . . . -31.91 70.26 0.0 OUTLIER 'Trans proline' 0 C--N 1.307 -1.608 0 C-N-CA 124.005 3.136 . . . . 0.0 113.787 -174.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.704 ' N ' ' O ' ' A' ' 63' ' ' ILE . . . -58.39 62.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.256 -0.903 . . . . 0.0 111.904 -177.67 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.545 ' N ' ' O ' ' A' ' 64' ' ' PRO . . . -101.77 83.49 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 119.447 -2.033 . . . . 0.0 109.257 -179.784 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . . . -72.31 112.24 8.22 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.975 -1.078 . . . . 0.0 108.364 -178.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . 0.412 ' H ' ' H ' ' A' ' 69' ' ' GLY . . . -176.17 -5.82 0.02 OUTLIER Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . 0.412 ' H ' ' H ' ' A' ' 68' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.98 . . . . . . . . 1 1 . 1 stop_ save_